Clinical indications for newer antifungal agents
نویسندگان
چکیده
منابع مشابه
Newer combination antifungal therapies for invasive aspergillosis.
Optimal therapy for invasive aspergillosis is unknown, and many clinicians have attempted to utilize a combination antifungal approach to improve outcomes. However, while numerous in vitro studies, animal models, and clinical reports suggest the possibility that combination antifungal therapy might offer improved results, there is no definitive accepted strategy. The currently available antifun...
متن کاملNewer anticoagulants should not be used for off-label indications.
e are presented here with a sketchy story of a presumed recent stroke onset that is embolic-looking while taking aspirin and clopidogrel for a coronary stent that had been inserted some 6 months earlier. Presumably, imaging consisting of computed tomography or magnetic resonance had shown large artery infarcts in differing arterial territories and of varying ages. Whether earlier infarcts had o...
متن کاملOutcomes of Allogeneic Stem Cell Transplant (allo-SCT) Recipients in the Era of Newer Antifungal Agents
© ISDS Annual Conference Proceedings 2013. This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License ( http://creativecommons.org/licenses/by-nc/3.0/), which permits distribution, public display, and publicly performance, making multiple copies, distribution of derivative works, provided the original work is properly cited....
متن کاملComparison of the in vitro activities of newer triazoles and established antifungal agents against Trichophyton rubrum.
One hundred eleven clinical Trichophyton rubrum isolates were tested against 7 antifungal agents. The geometric mean MICs of all isolates were, in increasing order: terbinafine, 0.03 mg/liter; voriconazole, 0.05 mg/liter; posaconazole, 0.11 mg/liter; isavuconazole, 0.13 mg/liter; itraconazole, 0.26 mg/liter; griseofulvin, 1.65 mg/liter; and fluconazole, 2.12 mg/liter.
متن کاملIndications for Neuromuscular Blocking Agents
©International Anesthesia Research Society. Unauthorized Use Prohibited. Almost thirty years ago, residual neuromuscular blockade was documented in a surprisingly high proportion of patients (30%), despite an almost systematic use of anticholinesterase agents.1 Since then, even with the development of shorter-acting neuromuscular blockers, pharmacological reversal, and more widespread use of ne...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Hospital Medicine
سال: 2009
ISSN: 1553-5592,1553-5606
DOI: 10.1002/jhm.412